{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015525","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.012619+00:00","generated_at":"2026-05-30T00:56:58.496808+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptimmune reports Q3 net loss $17.6M; plans 33% headcount cut, $300M in savings through 2028","bullets":["Q3 net loss $17.6M (EPS -$0.01); revenue $40.9M up from $7.3M due to Genentech/Astellas termination revenue.","Plans 33% headcount reduction in Q1 2025; expects $300M cost savings over 4 years, targeting breakeven in 2027.","Tecelra launch: 9 ATCs active, first patient apheresed; commercial revenues expected in Q4.","Lete-cel pivotal trial: 42% ORR (6 CR, 21 PR) in synovial sarcoma/MRCLS; BLA planned by end-2025.","Ended Q3 with total liquidity $186.1M; ceasing SURPASS-3 trial for ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015525","json":"https://secwatch.observer/filing/0001558370-24-015525.json","markdown":"https://secwatch.observer/filing/0001558370-24-015525.md","text":"https://secwatch.observer/filing/0001558370-24-015525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/0001558370-24-015525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/adap-20241113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:56:58.496808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f561117340ef0427e345515483db7f2b6a3c4be","claim":"Adaptimmune Therapeutics PLC announced a restructuring with charges of pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $9-11 million affecting workforce reduction of approximately 33% (33% reduction in workforce).","evidence_excerpt":"of 2025. The Company estimates that the pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $9-11 million with the majority of such costs being incurred in the first quarter of 2025. The Company will provide further updates as it progresses through the restructuring","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/0001558370-24-015525-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $9-11 million"},{"label":"Affected area","value":"workforce reduction of approximately 33%"},{"label":"Headcount","value":"33% reduction in workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}